Indications for primary and secondary exenterations in patients with cervical cancer

Gynecologic Oncology

Volumn 103, Issue 3, 2006, Pages 1023-1030

  Marnitz, Simone ^a   Köhler, Christhardt ^a   Müller, Marianne ^b   Behrens, Katja ^c   Hasenbein, Kati ^a   Schneider, Achim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Complication; Indication; Palliative exenteration; Pelvic exenteration; Primary cervical cancer; Recurrent cervical cancer

Indexed keywords

ADULT; AGED; ANAMNESIS; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHOLECYSTITIS; CHRONOTHERAPY; CLINICAL INDICATOR; DATA ANALYSIS; DEEP VEIN THROMBOSIS; DEVICE REMOVAL; DIGESTIVE SYSTEM FISTULA; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL SYMPTOM; GERMANY; GROUPS BY AGE; GYNECOLOGY; HISTOPATHOLOGY; HUMAN; ILEUS; INFECTION COMPLICATION; INTERMETHOD COMPARISON; LAPAROSCOPY; LUNG EMBOLISM; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL SCHOOL; OVERALL SURVIVAL; PELVIS EXENTERATION; PELVIS LYMPH NODE; PERIOPERATIVE PERIOD; PERITONITIS; PERONEUS NERVE PARALYSIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RECTOVAGINAL FISTULA; RECURRENT CANCER; REOPERATION; RETROSPECTIVE STUDY; SEPSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURGICAL APPROACH; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; URETER STENT; UTERINE CERVIX CARCINOMA;

ADULT; AGED; FEMALE; GERMANY; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PALLIATIVE CARE; PELVIC EXENTERATION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 33751424654     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.06.027     Document Type: Article

References (57)

1. Barber H.R.K. Relative prognostic significance of preoperative and operative findings in pelvic exenteration. Surg. Clin. North Am. 49 2 (1969) 431-447
2. Bricker E.M. Bladder substitution after pelvic evisceration. Surg. Clin. North Am. 30 5 (1950) 1511-1521
3. Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma. Cancer 1 (1948) 177-183
4. Berek J.S., Howe C., Lagasse L.D., and Hacker N.F. Pelvic exenteration for recurrent gynaecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol. Oncol. 99 1 (2005) 153-159
5. Chi D.S., Gemignani M.L., Curtin J.P., and Hoskins W.J. Long-term experience in the surgical management of cancer of the uterine cervix. Semin. Surg. Oncol. 17 (1999) 161-167
6. Crowe P.J., Temple W.J., Lopez M.J., and Ketcham A.S. Pelvic exenteration for advanced pelvic malignancy. Semin. Surg. Oncol. 17 (1999) 152-160
7. Crozier M., Morris M., Levenback C., Lucas K.R., Atkinson E.N., and Wharton J.T. Pelvic exenteration for adenocarcinoma of the uterine cervix. Gynecol. Oncol. 58 (1995) 74-78
8. del Carmen M.G., McIntyre J.F., and Goodman A. The role of intraoperative radiation therapy (IORT) in the treatment of locally advanced gynaecologic malignancies. Oncologist 5 (2000) 18-25
9. Downs L.S., Judson P.L., Argenta P.A., Carson L.F., and Boente M.P. A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer. Gynecol. Oncol. 95 (2004) 347-351
10. Estape R., and Angioli R. Surgical management of advanced and recurrent cervical cancer. Semin. Surg. Oncol. 16 (1999) 236-241
11. Friedberg V. Ergebnisse von 108 Exenterationsoperationen bei fortgeschrittenen gynäkologischen Karzinomen. Geburtsh Frauenheilk 49 (1989) 423-427
12. Gemignani M.L., Alektiar K.M., Leitao M., Mychalczak B., Chi D., Venkatraman E., et al. Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers. Int. J. Radiat. Oncol. Biol. Phys. 50 3 (2001) 687-694
13. Goldberg J.M., Piver S., Hempling R.E., Aiduk C., Blumenson L., and Recio F.O. Improvement in pelvic exenteration: factors responsible for reducing morbidity and mortality. Ann. Surg. Oncol. 5 (1998) 399-406
14. Hatch K.D., Shingelton H.M., Soong S.-J., Baker V.V., and Gelder M.S. Anterior pelvic exenteration. Gynecol. Oncol. 31 (1988) 205-213
15. Hawighorst-Knapstein S., Fusshoeller C., Franz C., Trautman K., Schmidt M., Pilch H., et al. The impact of treatment for genital cancer on quality of live and body image-Results of a prospective longitudinal 10-year study. Gynecol. Oncol. 94 (2004) 398-403
16. Höckel M. Laterally extended endopelvic resection-Novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic side wall. Gynecol. Oncol. 91 (2003) 369-377
17. Houvenaeghel G., Moutardier V., Karsenty G., Bladou F., Lelong B., Buttarelli M., et al. Major complications of urinary diversion after pelvic exenteration for gynecologic malignancies: a 23-year mono-institutional experience in 124 patients. Gynecol. Oncol. 92 (2004) 680-683
18. Hreshchyshyn M.M., Aron B.S., Boronow R.C., Franklin E.W., Shingelton H.M., and Blessing J.A. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int. J. Radiat. Oncol. Biol. Phys. 5 (1979) 317-322
19. Husain A., Curtin J., Brown C., Chi D., Hoskins W., Poynor E., et al. Continent urinary diversion and low-rectal anastomosis in patients undergoing exenterative procedures for recurrent gynecologic malignancies. Gynecol. Oncol. 78 (2000) 208-211
20. Ingiulla W., and Cosmi E.V. Pelvic exenteration for advanced carcinoma of the cervix. Am. J. Obstet. Gynecol. 99 8 (1967) 1083-1086
21. Karsenty G., Moutardier V., Lelong B., Guiramand J., Houvenaeghel G., Delpero J.R., et al. Long-term follow up of continent urinary diversion after pelvic exenteration for gynecologic malignancies. Gynecol. Oncol. 97 (2005) 524-528
22. Kasamatsu T., Onda T., Yamada T., and Tsunematsu R. Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma. Int. J. Gynecol. Obstet. 89 (2005) 39-44
23. Ketcham A.S., Deckers P.J., Sugarbaker E.V., Hoye R.C., Thomas L.B., and Smith R.R. Pelvic exenteration for carcinoma of the uterine cervix-A 15-year experience. Cancer 26 3 (1970) 513-521
24. Köhler C., Tozzi R., Possover M., and Schneider A. Explorative laparoscopy prior to exenterative surgery. Gynecol. Oncol. 86 (2002) 311-315
25. Lambrou N.C., Pearson J.M., and Averette H.E. Pelvic exenteration of gynecologic malignancy: indications, and technical and reconstructive considerations. Surg. Oncol. Clin. N. Am. 14 (2005) 289-300
26. Lawhead R.A., Clark D.G.C., Smith D.H., Pierce V.K., and Lewis J.L. Pelvic exenteration for recurrent or persistent gynaecologic malignancies: a 10-year review of the Memorial-Sloan-Kettering Cancer Center experience (1972-1981). Gynecol. Oncol. 33 (1989) 279-282
27. Lin M.Y., Fan E.W., Chiu A.W., Tian Y.F., Wu M.P., and Liao A.C. Laparoscopy-assisted transvaginal total exenteration for locally advanced cervical cancer with bladder invasion after radiotherapy. J. Endourol. 18 9 (2004) 867-870
28. Long H.J., Bundy B.N., Grendys Jr. E.C., Benda J.A., McMeekin D.S., Sorosky J., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 23 (2005) 4626-4633
29. Lopez-Graniel C., Dolores R., Cetina L., Gonzales A., Cantu D., Chanona J., et al. Pre-exenterative chemotherapy, a novel approach for patients with persistent or recurrent cervical cancer. BMC Cancer 118 (2005)
30. Magrina J.F., Stanhope C.R., and Waever A.L. Pelvic exenterations: supralevator, infralevator, and with vulvectomy. Gynecol. Oncol. 64 (1997) 130-135
31. Matthews C.M., Morris M., Burke T.W., Gershenson D.M., Wharton T., and Rutledge F.N. Pelvic exenteration in the elderly patient. Obstet. Gynecol. 79 (1992) 773-777
32. Million R.R., Rutledge F., and Fletcher G.H. Stage IV carcinoma of the cervix with bladder invasion. Am. J. Obstet. Gynecol. 113 2 (1972) 239-246
33. Moore D.H., Blessing J.A., McQuellon R.P., Thaler H.T., Cella D., Benda J., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 22 15 (2004) 3113-3119
34. Morley G.W., Hopkins M.P., Lindenauer S.M., and Roberts J.A. Pelvic exenteration, university of Michigan: 100 patients at 5 years. Obstet. Gynecol. 74 (1989) 934-943
35. Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenbeck C., Stevens R.E., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. NEJM 340 15 (1999) 1137-1143
36. Moutardier V., Houvenaeghel G., Lelong B., Mokart D., and Delpero J.R. Colorectal function preservation in posterior ant total supralevator exenteration for gynaecologic malignancies: an 89-patient series. Gynecol. Oncol. 89 (2003) 155-159
37. Nagao S., Fujiwara K., Oda T., Ishikawa H., Koike H., Tanaka H., et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol. Oncol. 96 (2005) 805-809
38. Numa F., Ogata H., Suminami Y., Tsunaga N., Nakamura Y., Tamura H., et al. Pelvic exenteration for the treatment of gynecological malignancies. Arch. Gynecol. Obstet. 259 (1997) 133-138
39. Pearcey R., Brundage M., Drouin P., Jeffrey J., Johnston D., Lukka H., et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J. Clin. Oncol. 20 4 (2002) 966-972
40. Pomel C., Rouzier R., Pocard M., Thoury A., Sideris L., Morice P., et al. Laparoscopic total pelvic exenteration for cervical cancer relapse. Gynecol. Oncol. 91 (2003) 616-618
41. Roberts W.S., Cavanagh D., Bryson P., Lyman G.H., and Hewitt S. Major morbidity after pelvic exenteration. A seven-year experience. Obstet. Gynecol. 69 4 (1987) 617-621
42. Robertson G., Lopes A., Beynon G., and Monaghan J.M. Pelvic exenteration: a review of the Gateshead experience 1974-1992. Br. J. Obstet. Gynecol. 101 (1994) 529-531
43. Roos E.J., de Graeff A., van Eijkeren M.A., Boon T.A., and Heintz A.P.M. Quality of live after pelvic exenteration. Gynecol. Oncol. 93 (2004) 610-614
44. Roos E.J., van Eijkeren M.A., Boon T.A., and Heintz A.P.M. Pelvic exenteration as treatment of recurrent gynecologic and urologic cancer. Int. J. Gynecol. Cancer 15 (2005) 624-629
45. Rose P.G., Blessing J.A., Buller R.E., Mannel R.S., and Webster K.D. Prolonged oral etoposide in recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol. Oncol. 89 (2003) 267-270
46. Rutledge F.N., Smith J.P., Wharton J.T., and O'Quinn A.G. Pelvic exenteration: analysis of 296 patients. Am. J. Obstet. Gynecol. 129 (1977) 881-892
47. Saunders N. Pelvic exenteration: by whom and for whom?. Lancet 345 (1995) 5-6
48. Sharma S., Odunsi K., Driscoll D., and Lele S. Pelvic exenteration for gynecological malignancies: twenty-year experience at Rosewell Park Cancer Institute. Int. J. Gynecol. Cancer 15 (2005) 475-482
49. Shingelton H.M., Soong S.J., Gelder M.S., Hatch K.D., Baker V.V., and Austin J.M. Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet. Gynecol. 73 (1989) 1027-1034
50. Soper J.T., Berchuck A., Creasman W.T., and Clarke-Pearson D.L. Pelvic exenteration: factors associated with major surgical morbidity. Gynecol. Oncol. 35 (1989) 93-98
51. Stanhope C.R., and Symmonds R.E. Palliative exenteration-What, when, and why?. Am. J. Obstet. Gynecol. 152 (1985) 12-16
52. Stehman F.B., Bundy B.N., Thomas G., Keys H.M., d'Ablaing G., Fowler W.C., Mortel R., and Creasman W.T. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of an Gynecologic Oncology Group trial. J. Clin. Oncol. 11 (1993) 1523-1528
53. Symmonds R.E., Pratt J.H., and Webb M.J. Exenterative operations: experience with 198 patients. Am. J. Obstet. Gynecol. 121 7 (1975) 907-918
54. Tambaro R., Scambia G., DiMaio M., Pisano C., Barletta E., Iaffaioli V.R., and Pignata S. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. Crit. Rev. Oncol./Hematol. 52 (2004) 33-44
55. Tiersten A.D., Selleck M.J., Hershman D.L., Smith D., Resnik E.E., Troxel A.B., Brafman L.B., and Shriberg L. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol. Oncol. 92 (2004) 635-638
56. Tinker A.V., Bhagat K., Swenerton K.D., and Hoskins P.J. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol. Oncol. 98 (2005) 54-58
57. Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler C.F., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecology Oncology Group and Southwest Oncology Group study. J. Clin. Oncol. 17 5 (1999) 1339-1348